iX Biopharma Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 42C.SI | AQST | IRWD | 2M7C.F | COLL | PCRX | |
|---|---|---|---|---|---|---|
| Market cap | 558.96M | 517.74M | 589.74M | 2.77B | 747.48M | 1.45B |
| P/E (TTM) | — | — | 4.6 | 14.3 | 18.1 | 103.9 |
| Forward P/E | 268.4 | -7.2 | 2.4 | — | 3.2 | 10.5 |
| Price/book | 36.4 | -9.1 | -3.6 | 1.2 | 2.4 | 2.2 |
| Dividend yield | — | — | — | 3.24% | — | — |
| 1-year change | +523.46% | −40.79% | +131.21% | −20.00% | −34.95% | +69.29% |
| Today | +0.99% | +1.85% | −1.68% | −1.72% | −1.16% | −0.08% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 42C.SI news ›iX BIOPHARMA: KGI Initiates Coverage With S$1.17 Target Price. Why Bullish?
▪ Wafermine® Emergency Use Authorization (EUA) pathway at final regulatory step. A US emergency declaration published on 3 September 2026 allows FDA to consider drugs for moderate-to-severe acute pain in military casualties.iX expects to…
iX Biopharma details Wafermine milestones and U.S. compounding push ahead of AGM
iX Biopharma Ltd. ( (SG:42C) ) just unveiled an announcement. The most recent analyst rating on (SG:42C) stock is a Buy with a S$1.00 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
nextinsight.net2
-
longbridge.com1
-
theglobeandmail.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.